The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Randomized Trial of Genotype-Guided Versus Standard Warfarin Dosing in Patients Initiating Oral Anticoagulation
Open accessAbstract
Background— Pharmacogenetic-guided dosing of warfarin is a promising application of “personalized medicine” but has not been adequately tested in randomized trials. Methods and Results— Consenting patients (n=206) being initiated on warfarin were randomized to pharmacogenetic-guided or standard dosing. Buccal swab DNA was genotyped for CYP2C9 *2 and CYP2C9 * 3 and VKORC1 C1173T with a rapid assay. Standard dosing followed an empirical protocol, whereas pharmacogenetic-guided dosing followed a regression equation including the 3 genetic variants and age, sex, and weight. Prothrombin time international normalized ratio (INR) was measured routinely on days 0, 3, 5, 8, 21, 60, and 90. A research pharmacist unblinded to treatment strategy managed dose adjustments. Patients were followed up for up to 3 months. Pharmacogenetic-guided predicted doses more accurately approximated stable doses ( P <0.001), resulting in smaller ( P =0.002) and fewer ( P =0.03) dosing changes and INRs ( P =0.06). However, percent out-of-range INRs (pharmacogenetic=30.7%, standard=33.1%), the primary end point, did not differ significantly between arms. Despite this, when restricted to wild-type patients (who required larger doses; P =0.001) and multiple variant carriers (who required smaller doses; P <0.001) in exploratory analyses, results (pharmacogenetic=29%, standard=39%) achieved nominal significance ( P =0.03). Multiple variant allele carriers were at increased risk of an INR of ≥4 ( P =0.03). Conclusions— An algorithm guided by pharmacogenetic and clinical factors improved the accuracy and efficiency of warfarin dose initiation. Despite this, the primary end point of a reduction in out-of-range INRs was not achieved. In subset analyses, pharmacogenetic guidance showed promise for wild-type and multiple variant genotypes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pharmacogenomics: Translating Functional Genomics into Rational Therapeutics
Evans, W. E., & Relling, M. V. (1999) · Science · doi:10.1126/science.286.5439.487 · Cited by 2,475
A Method to Determine the Optimal Intensity of Oral Anticoagulant Therapy
Rosendaal, F. R., Cannegieter, S. C., van der Meer, F. J. M., & Briët, E. (1993) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1651587 · Cited by 2,065
Effect of VKORC1 Haplotypes on Transcriptional Regulation and Warfarin Dose
Rieder, M. J., Reiner, A. P., Gage, B. F., Nickerson, D. A., Eby, C. S., McLeod, H. L., Blough, D. K., Thummel, K. E., Veenstra, D. L., & Rettie, A. E. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044503 · Cited by 1,399
Aithal, G. P., Day, C. P., Kesteven, P. J., & Daly, A. K. (1999) · The Lancet · doi:10.1016/s0140-6736(98)04474-2 · Cited by 1,243
Higashi, M. K. (2002) · JAMA · doi:10.1001/jama.287.13.1690 · Cited by 1,048
Sconce, E. A., Khan, T. I., Wynne, H. A., Avery, P., Monkhouse, L., King, B. P., Wood, P., Kesteven, P., Daly, A. K., & Kamali, F. (2005) · Blood · doi:10.1182/blood-2005-03-1108 · Cited by 947
A physical map of the human genome
The International Human Genome Mapping Consortium, Washington University School of Medicine, G. S. C., McPherson, J. D., Marra, M., Hillier, L., Waterston, R. H., Chinwalla, A., Wallis, J., Sekhon, M., Wylie, K., et al. (2001) · Nature · doi:10.1038/35057157 · Cited by 925
Hylek, E. M., Skates, S. J., Sheehan, M. A., & Singer, D. E. (1996) · New England Journal of Medicine · doi:10.1056/nejm199608223350802 · Cited by 789
Low-Molecular-Weight Heparin in the Treatment of Patients with Venous Thromboembolism
(1997) · New England Journal of Medicine · doi:10.1056/nejm199709043371001 · Cited by 784
D'Andrea, G., D'Ambrosio, R. L., Di Perna, P., Chetta, M., Santacroce, R., Brancaccio, V., Grandone, E., & Margaglione, M. (2005) · Blood · doi:10.1182/blood-2004-06-2111 · Cited by 699
Cited by
Ticagrelor versus clopidogrel in patients with acute coronary syndromes
Wallentin, L., Becker, R. C., Budaj, A., Cannon, C. P., Emanuelsson, H., Held, C., Horrow, J., Husted, S., James, S., Katus, H., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904327 · Cited by 7,117
A Prospective Natural-History Study of Coronary Atherosclerosis
Stone, G. W., Maehara, A., Lansky, A. J., de Bruyne, B., Cristea, E., Mintz, G. S., Mehran, R., McPherson, J., Farhat, N., Marso, S. P., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1002358 · Cited by 3,276
Precision medicine, AI, and the future of personalized health care
Johnson, K. B., Wei, W., Weeraratne, D., Frisse, M. E., Misulis, K., Rhee, K., Zhao, J., & Snowdon, J. L. (2021) · Clinical and Translational Science · doi:10.1111/cts.12884 · Cited by 1,854
Genetic Determinants of Response to Clopidogrel and Cardiovascular Events
Simon, T., Verstuyft, C., Mary-Krause, M., Quteineh, L., Drouet, E., Méneveau, N., Steg, P. G., Ferrières, J., Danchin, N., & Becquemont, L. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808227 · Cited by 1,728
Early Diagnosis of Myocardial Infarction with Sensitive Cardiac Troponin Assays
Reichlin, T., Hochholzer, W., Bassetti, S., Steuer, S., Stelzig, C., Hartwiger, S., Biedert, S., Schaub, N., Buerge, C., Potocki, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900428 · Cited by 1,687
Estimation of the Warfarin Dose with Clinical and Pharmacogenetic Data
(2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809329 · Cited by 1,577
Ageno, W., Gallus, A. S., Wittkowsky, A., Crowther, M., Hylek, E. M., & Palareti, G. (2012) · Chest · doi:10.1378/chest.11-2292 · Cited by 1,503
European Resuscitation Council Guidelines for Resuscitation 2010 Section 1. Executive summary
Nolan, J. P., Soar, J., Zideman, D. A., Biarent, D., Bossaert, L. L., Deakin, C., Koster, R. W., Wyllie, J., & Böttiger, B. (2010) · Resuscitation · doi:10.1016/j.resuscitation.2010.08.021 · Cited by 1,375
Evidence-Based Management of Anticoagulant Therapy
Holbrook, A., Schulman, S., Witt, D. M., Vandvik, P. O., Fish, J., Kovacs, M. J., Svensson, P. J., Veenstra, D. L., Crowther, M., & Guyatt, G. H. (2012) · Chest · doi:10.1378/chest.11-2295 · Cited by 1,269
Anderson, J. L., & Morrow, D. A. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1606915 · Cited by 1,115
Self-citationUse of Pharmacogenetic and Clinical Factors to Predict the Therapeutic Dose of Warfarin
Gage, B., Eby, C., Johnson, J., Deych, E., Rieder, M., Ridker, P., Milligan, P., Grice, G., Lenzini, P., Rettie, A., et al. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.10 · Cited by 847
A Randomized Trial of Genotype-Guided Dosing of Warfarin
Pirmohamed, M., Burnside, G., Eriksson, N., Jorgensen, A. L., Toh, C. H., Nicholson, T., Kesteven, P., Christersson, C., Wahlström, B., Stafberg, C., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1311386 · Cited by 811
A Pharmacogenetic versus a Clinical Algorithm for Warfarin Dosing
Kimmel, S. E., French, B., Kasner, S. E., Johnson, J. A., Anderson, J. L., Gage, B. F., Rosenberg, Y. D., Eby, C. S., Madigan, R. A., McBane, R. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1310669 · Cited by 742
Self-citationJohnson, J. A., Gong, L., Whirl-Carrillo, M., Gage, B. F., Scott, S. A., Stein, C. M., Anderson, J. L., Kimmel, S. E., Lee, M. T. M., Pirmohamed, M., et al. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.185 · Cited by 647
Self-citationTakeuchi, F., McGinnis, R., Bourgeois, S., Barnes, C., Eriksson, N., Soranzo, N., Whittaker, P., Ranganath, V., Kumanduri, V., McLaren, W., et al. (2009) · PLoS Genetics · doi:10.1371/journal.pgen.1000433 · Cited by 632
Chiral Toxicology: It's the Same Thing…Only Different
Smith, S. W. (2009) · Toxicological Sciences · doi:10.1093/toxsci/kfp097 · Cited by 602
The largest prospective warfarin-treated cohort supports genetic forecasting
Wadelius, M., Chen, L. Y., Lindh, J. D., Eriksson, N., Ghori, M. J. R., Bumpstead, S., Holm, L., McGinnis, R., Rane, A., & Deloukas, P. (2009) · Blood · doi:10.1182/blood-2008-04-149070 · Cited by 550
CYP4F2 genetic variant alters required warfarin dose
Caldwell, M. D., Awad, T., Johnson, J. A., Gage, B. F., Falkowski, M., Gardina, P., Hubbard, J., Turpaz, Y., Langaee, T. Y., Eby, C., et al. (2008) · Blood · doi:10.1182/blood-2007-11-122010 · Cited by 521
A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose
Cooper, G. M., Johnson, J. A., Langaee, T. Y., Feng, H., Stanaway, I. B., Schwarz, U. I., Ritchie, M. D., Stein, C. M., Roden, D. M., Smith, J. D., et al. (2008) · Blood · doi:10.1182/blood-2008-01-134247 · Cited by 481
Steg, P. G., Huber, K., Andreotti, F., Arnesen, H., Atar, D., Badimon, L., Bassand, J.-P., De Caterina, R., Eikelboom, J. A., Gulba, D., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr204 · Cited by 395
Giglia, T. M., Massicotte, M. P., Tweddell, J. S., Barst, R. J., Bauman, M., Erickson, C. C., Feltes, T. F., Foster, E., Hinoki, K., Ichord, R. N., et al. (2013) · Circulation · doi:10.1161/01.cir.0000436140.77832.7a · Cited by 390
Massively Parallel Sequencing: The Next Big Thing in Genetic Medicine
Tucker, T., Marra, M., & Friedman, J. M. (2009) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2009.06.022 · Cited by 386
Becker, R. C., Bassand, J. P., Budaj, A., Wojdyla, D. M., James, S. K., Cornel, J. H., French, J., Held, C., Horrow, J., Husted, S., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr422 · Cited by 383
Warfarin Genotyping Reduces Hospitalization Rates
Epstein, R. S., Moyer, T. P., Aubert, R. E., O'Kane, D. J., Xia, F., Verbrugge, R. R., Gage, B. F., & Teagarden, J. R. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.03.009 · Cited by 336
Delivery of Genomic Medicine for Common Chronic Adult Diseases: A Systematic Review
Scheuner, M. T., Sieverding, P., & Shekelle, P. G. (2008) · JAMA · doi:10.1001/jama.299.11.1320 · Cited by 305
Eckman, M. H., Rosand, J., Greenberg, S. M., & Gage, B. F. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-2-200901200-00005 · Cited by 283
Clinical Decision Support: a 25 Year Retrospective and a 25 Year Vision
Sittig, D. F., Wright, A., & Middleton, B. (2016) · Yearbook of Medical Informatics · doi:10.15265/iys-2016-s034 · Cited by 277
Computerized advice on drug dosage to improve prescribing practice
Durieux, P., Trinquart, L., Colombet, I., Niès, J., Walton, R., Rajeswaran, A., Rège-Walther, M., Harvey, E., & Burnand, B. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002894.pub2 · Cited by 253
Pharmacogenetic variation at CYP2C9, CYP2C19, and CYP2D6 at global and microgeographic scales
Sistonen, J., Fuselli, S., Palo, J. U., Chauhan, N., Padh, H., & Sajantila, A. (2009) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32831ebb30 · Cited by 200
A policy model to evaluate the benefits, risks and costs of warfarin pharmacogenomic testing
Meckley, L. M., Gudgeon, J. M., Anderson, J. L., Williams, M. S., & Veenstra, D. L. (2010) · PharmacoEconomics · doi:10.2165/11318240-000000000-00000 · Cited by 97
Self-citationGenotype-Guided Dosing of Coumarin Anticoagulants: A Meta-analysis of Randomized Controlled Trials
Tang, T., Liu, J., Zuo, K., Cheng, J., Chen, L., Lu, C., Han, S., Xu, J., Jia, Z., Ye, M., et al. (2015) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248414565666 · Cited by 30
Metadata
- Authors
- Anderson, J. L., Horne, B. D., Stevens, S. M., Grove, A. S., Barton, S., Nicholas, Z. P., Kahn, S. F. S., May, H. T., Samuelson, K. M., Muhlestein, J. B., & Carlquist, J. F.
- Venue
- Circulation
- Published
- 2007-11-27
- Volume
- 116
- Issue
- 22
- Pages
- 2563-2570
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2157065952
- Cited by
- 727
- References
- 37
- FWCI
- 83.25
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.